Type 2 Diabetes Clinical Trial
— ENERGISEDOfficial title:
mHealth Intervention Delivered in General Practice to Increase Physical Activity and Reduce Sedentary Behaviour of Patients With Prediabetes and Type 2 Diabetes
NCT number | NCT05351359 |
Other study ID # | ENERGISED |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | April 25, 2022 |
Est. completion date | June 2024 |
Sedentary behaviour has a detrimental effect on the mortality, morbidity, and well-being of patients with type 2 diabetes and prediabetes, and general practitioners should advise patients on how to self-monitor and increase their physical activity. The emergence of mobile health (mHealth) technologies unlocks the potential to further improve physical behaviour using an innovative "just-in-time" adaptive approach whereby behavioural support is provided in real-time, based on data from wearable sensors. Thus, the investigators aim to evaluate the effect of a just-in-time mHealth intervention administered by general practitioners on the physical activity and sedentary behaviour of patients with type 2 diabetes and prediabetes. A total of 340 patients will be recruited from 20 general practices across the Czech Republic and randomly assigned to either an active control or intervention group. Both groups will receive brief physical activity advice from their general practitioners and a Fitbit fitness tracker to self-monitor their daily steps, but the intervention group will also receive a mHealth-enabled just-in-time adaptive intervention and regular monthly phone counselling in the first 6 months. The mHealth intervention will be delivered using a custom-developed system (HealthReact) connected to the Fitbit that will trigger just-in-time text messages. For example, a prompt to take a break from sedentary behaviour will be triggered after 30 sedentary minutes or a motivational message with a specific goal to take more steps will be triggered when the total step count is too low. The primary outcome will be the change in daily step count at 6 months, other outcomes include changes in other physical behaviour measures, blood tests, anthropometry and patient-reported outcomes at 6 and 12 months. If the intervention is effective, this study will provide a model of health prevention that can be directly implemented and commissioned within primary care using existing infrastructure.
Status | Recruiting |
Enrollment | 340 |
Est. completion date | June 2024 |
Est. primary completion date | September 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of prediabetes or T2DM according to the Czech guidelines for GPs on diabetes mellitus1 and prediabetes2, i.e. fasting plasma glucose 5.6-6.9 mmol/l, or 2-h plasma glucose of 7.8-11.0 mmol/l after ingestion of 75 g of oral glucose load for the diagnosis of prediabetes, and fasting plasma glucose = 7.0 mmol/l, or 2-h plasma glucose = 11.1 mmol/l after ingestion of 75 g of the oral glucose load for the diagnosis of T2DM - Age 18 years or older. - Registered at a participating general practice. - Regular users of a smartphone and willing to use it as part of the study. - Written informed consent obtained before any assessment related to the study. Exclusion Criteria: - unable to walk - pregnancy - taking insulin - living in a residential or nursing care home - co-morbid conditions that would affect their adherence to the trial procedures |
Country | Name | City | State |
---|---|---|---|
Czechia | Institute of General Practice | Prague |
Lead Sponsor | Collaborator |
---|---|
Charles University, Czech Republic | St George's, University of London, University Ghent, University of Hradec Kralove, University of Leicester |
Czechia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | step count | change in daily step count | from baseline to 12-month assessment | |
Secondary | chair-stand test | functional 30s chair-stand test | at 6 and 12 months | |
Secondary | HbA1c | haemoglobin A1c | at 6 and 12 months | |
Secondary | glycemia | fasting plasma glucose | at 6 and 12 months | |
Secondary | lipid profile | total cholesterol, LDL cholesterol, HDL cholesterol, triacylglycerids | at 12 months | |
Secondary | step count | change in daily step count | at 6 months | |
Secondary | physical behaviour - average acceleration | metric of physical activity volume | at 6 and 12 months | |
Secondary | physical behaviour - intensity gradient | metric of physical activity intensity | at 6 and 12 months | |
Secondary | sedentary time | time per day spent sedentary (in minutes) | at 6 and 12 months | |
Secondary | sedentary bouts | time per day (in minutes) spent sedentary in bouts of 30 mins and longer | at 6 and 12 months | |
Secondary | walking cadence | cadence (steps/min) in 5 (non-consecutive) highest-cadence minutes | at 6 and 12 months | |
Secondary | blood pressure | systolic and diastolic blood pressure | at 6 and 12 months | |
Secondary | Hospital Anxiety and Depression Scale (HADS) | symptoms of anxiety and depression: 14 items on a scale 0-3 (a higher score means a worse outcome) | at 6 and 12 months | |
Secondary | Short Form Survey (SF-12) | measure of health-related quality of life: 12 items using various scales converted to a score 0-100 (a higher score means a better outcome) | at 6 and 12 months | |
Secondary | body mass index | weigh in kilograms divided by height in meters squared | at 6 and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |